Breakthrough

Early detection of leukemia patients' resistance to therapy

Australian researchers have made a world-first breakthrough in the early detection of patients' resistance to a common treatment for chronic myeloid leukemia. The discovery offers some hope that the patients' treatment could be changed sooner to improve their chances of survival.

Dr Laura Eadie, Postdoctoral Researcher, Cancer Theme, SAHMRI; School of...
Dr Laura Eadie, Postdoctoral Researcher, Cancer Theme, SAHMRI; School of Medicine, University of Adelaide.
Source: SAHMRI

The researchers – based in the Cancer Theme at the South Australian Health & Medical Research Institute (SAHMRI) and the University of Adelaide's School of Medicine – have developed a new test that they believe could be adopted by doctors worldwide.

Lead author and postdoctoral researcher Dr Laura Eadie says one-in-five chronic myeloid leukemia (CML) patients are resistant to the leading treatment of their condition. "The development of the targeted drug Glivec for chronic myeloid leukemia has been one of the most remarkable success stories in cancer treatment over the past two decades. This is because the drug targets the mutant protein that causes their leukemia," Dr Eadie says. "However, about 20% of patients have a poor response to Glivec, and until now we haven't fully understood why. Unfortunately, this means that one-in-five patients could be receiving treatment that ultimately is not benefitting them, losing response to therapy and reducing their chances of survival."

The study looked at the role of P-glycoprotein, a protein that pumps many drugs – including Glivec – out of leukemia cells. "Some patients were found to have higher levels of P-glycoprotein in their leukemic cells after just a few weeks of starting therapy. These patients were much more likely to develop resistance to Glivec later on," Dr Eadie says. "We've found the greater the increase in P-glycoprotein in patients, the greater their risk is of becoming resistant and not responding to their drug any more, or even succumbing to their disease."

The research team's work shows, for the first time, that assessing a patient's levels of the P-glycoprotein soon after they start receiving Glivec therapy will help to predict that patient’s long-term response to the drug. "This new test, developed in our laboratory, may provide an opportunity for doctors around the world to change treatment strategies for those patients most at risk of doing poorly on Glivec before they actually lose response to the therapy," Dr Eadie says.

Dr Eadie is also the recipient of a 2016 Fulbright South Australia Postdoctoral Scholarship. In August she will travel to the United States to continue research into leukemia, based at the St. Jude Children’s Research Hospital in Tennessee. This work will continue her focus on the effectiveness of leukemia treatments and the mechanisms of resistance in patients. "I hope that by better understanding the key drivers of response and resistance in patients, these research findings will help to inform clinical practice and ensure the best possible chance of patient survival," she says.


Source: University of Adelaide

08.08.2016

Read all latest stories

Related articles

Photo

News • Oncology

Loophole for cancer cells

Many cancers only become a mortal danger if they form metastases elsewhere in the body. Such secondary tumours are formed when individual cells break away from the main tumour and travel through the…

Photo

News • Liquid biopsy for early detection of brain tumours

Glioblastoma: Mathematical modelling could lead to simple blood test

The development of a simple blood test for glioblastomas could mean earlier diagnosis and more effective and personalised treatment options against the most common type of malignant brain cancer.

Photo

News • Cancer research

How the body fights back against leukemia

New research from the University of East Anglia (UEA) and Quadram Institute reveals how our immune system can be triggered to attack cancer cells.

Related products

Mindray – BC-6800Plus Auto Hematology Analyzer

Blood Cell Couner

Mindray – BC-6800Plus Auto Hematology Analyzer

Shenzhen Mindray Bio-Medical Electronics Co., Ltd
MolGen – PurePrep 96

Extraction

MolGen – PurePrep 96

MolGen
Alsachim - Dosimmune immunosupressant Alsachim – kit (CE-IVD or RUO)

Clinical Chemistry

Alsachim - Dosimmune immunosupressant Alsachim – kit (CE-IVD or RUO)

Alsachim, a Shimadzu Group Company
Alsachim – Dosinaco anticoagulant reagent kit (RUO)

Clinical Chemistry

Alsachim – Dosinaco anticoagulant reagent kit (RUO)

Alsachim, a Shimadzu Group Company
Beckman Coulter – Access Procalcitonin (PCT)

Immunoassays

Beckman Coulter – Access Procalcitonin (PCT)

Beckman Coulter Diagnostics
Subscribe to Newsletter